Literature DB >> 17140950

Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure.

Nikolaos Bonaros1, Rauend Rauf, Dominik Wolf, Eva Margreiter, Alexandar Tzankov, Bernhard Schlechta, Alfred Kocher, Harald Ott, Thomas Schachner, Steffen Hering, Johannes Bonatti, Guenther Laufer.   

Abstract

OBJECTIVES: Cellular cardiomyoplasty using skeletal myoblasts or angiopoietic progenitor cells offers a promising approach for the treatment of ischemic heart failure. Although several studies have shown encouraging results in acute myocardial infarction, the efficacy of cell therapy using skeletal myoblasts and angiopoietic progenitor cells in chronic ischemic heart disease remains undetermined.
METHODS: Ischemic heart failure was induced by left anterior descending coronary artery ligation in nude rats: (1) Culture medium, (2) homologous skeletal myoblasts (SM), (3) human AC-133+ cells (SC), and (4) both skeletal myoblasts and AC-133+ cells (Comb) were injected in the infarct (SM) and peri-infarct area (SC) 4 weeks after infarction. Assessment of myocardial function included echocardiography 4 weeks after cell delivery. Histology was based on quantification of myocardial fibrosis, apoptosis, and capillary density.
RESULTS: Left ventricular dilatation was attenuated and ejection fraction improved significantly after cell transplantation (SM: 59.4% +/- 8.8%, SC: 60.3% +/- 6.6%, Comb: 68.2% +/- 5.6% vs control: 41.5% +/- 7.4%, P = .0013). Quantification of scar tissue showed a significant reduction of infarct area in cell-treated animals (SM: 22.3% +/- 9.1%, SC: 19.8% +/- 7.6%, Comb: 13.2% +/- 5.8% vs controls: 36.5% +/- 8.2%, P = .008). Improvement of myocardial function was associated with reduced apoptotic index (SM: 3.2% +/- 0.9%, SC: 3.1% +/- 0.6%, Comb: 1.8% +/- 0.8% vs controls: 10.3% +/- 1.6%, P = .0002) and increased vascular density (SM: 5.2 +/- 1.2, SC: 8.3 +/- 1.8, Comb: 12.3 +/- 2.3, controls: 1.9 +/- 0.3, all capillary vessels/high-power field, P = .007) in animals after cellular cardiomyoplasty.
CONCLUSIONS: Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells results in ventricular function improvement, reduction of scar size and myocardial apoptosis, and increased neoangiogenesis in chronic ischemia. Clinical studies are warranted to prove this new therapeutic concept.

Entities:  

Mesh:

Year:  2006        PMID: 17140950     DOI: 10.1016/j.jtcvs.2006.07.023

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  11 in total

Review 1.  Stem cells and cardiac repair: a critical analysis.

Authors:  Jonathan H Dinsmore; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2008-01-31       Impact factor: 4.132

Review 2.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 3.  Programming and reprogramming a human heart cell.

Authors:  Makoto Sahara; Federica Santoro; Kenneth R Chien
Journal:  EMBO J       Date:  2015-02-20       Impact factor: 11.598

Review 4.  Stem cell therapy for chronic myocardial infarction.

Authors:  Manuel Mazo; Beatriz Pelacho; Felipe Prósper
Journal:  J Cardiovasc Transl Res       Date:  2010-01-21       Impact factor: 4.132

Review 5.  Stem cells and diabetic cardiomyopathy: from pathology to therapy.

Authors:  Mingfei Liu; Han Chen; Jun Jiang; Zhaocai Zhang; Chen Wang; Na Zhang; Liang Dong; Xinyang Hu; Wei Zhu; Hong Yu; Jian'an Wang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

6.  Animal models of cardiac disease and stem cell therapy.

Authors:  Lailiang Ou; Wenzhong Li; Yi Liu; Yue Zhang; Shen Jie; Deling Kong; Gustav Steinhoff; Nan Ma
Journal:  Open Cardiovasc Med J       Date:  2010-11-26

7.  Cellular cardiomyoplasty and cardiac regeneration.

Authors:  Lakshmana Pendyala; Traci Goodchild; Radhika R Gadesam; Jack Chen; Keith Robinson; Nicolas Chronos; Dongming Hou
Journal:  Curr Cardiol Rev       Date:  2008-05

8.  The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells.

Authors:  Karin Albrecht-Schgoer; Wilfried Schgoer; Johannes Holfeld; Markus Theurl; Dominik Wiedemann; Christina Steger; Rajesh Gupta; Severin Semsroth; Reiner Fischer-Colbrie; Arno G E Beer; Ursula Stanzl; Eva Huber; Sol Misener; Daniel Dejaco; Raj Kishore; Otmar Pachinger; Michael Grimm; Nikolaos Bonaros; Rudolf Kirchmair
Journal:  Circulation       Date:  2012-10-18       Impact factor: 29.690

9.  Choice of cell-delivery route for skeletal myoblast transplantation for treating post-infarction chronic heart failure in rat.

Authors:  Satsuki Fukushima; Steven R Coppen; Joon Lee; Kenichi Yamahara; Leanne E Felkin; Cesare M N Terracciano; Paul J R Barton; Magdi H Yacoub; Ken Suzuki
Journal:  PLoS One       Date:  2008-08-27       Impact factor: 3.240

Review 10.  Metabolic modulation and cellular therapy of cardiac dysfunction and failure.

Authors:  Diana Revenco; James P Morgan
Journal:  J Cell Mol Med       Date:  2009-04-20       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.